Hub : Traits :

Medication: Simvastatin

131 significantly associated models · 49 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	61510619	63844736	4	1	8.3e-12	2.4e-12	1.0e+00	100	DOCK7
2	1	108854166	110742615	8	1	9.1e-36	7.0e-36	1.0e+00	100	PSRC1
3	2	20529948	21958745	1	1	8.6e-25	2.0e-25	1.0e+00	100	APOB
4	2	27467598	27949052	1	1	1.7e-09	1.2e-09	1.0e+00	100	FNDC4
5	2	43791363	44450524	2	2	6.1e-08	9.5e-18	1.3e-09	50	ABCG5 LRPPRC
6	5	73969058	75504243	2	1	1.6e-10	1.3e-10	1.0e-01	94	HMGCR
7	8	18003897	18505600	1	1	1.4e-09	7.4e-11	1.5e-02	86	NAT2
8	8	19547307	20071503	1	1	5.4e-08	6.2e-09	2.2e-03	72	LPL
9	9	135883620	136399075	1	1	3.7e-08	9.6e-09	3.1e-03	73	ABO
10	11	8725268	10159883	1	1	6.1e-08	2.0e-04	9.7e-03	52	IPO7
11	11	115953897	117745003	2	2	7.3e-15	7.8e-16	3.1e-01	98	PAFAH1B2 ZNF259
12	15	90730363	92135418	1	1	3.4e-08	7.2e-08	1.0e+00	100	FES
13	16	56749994	57261146	1	1	8.9e-08	8.9e-08	1.0e+00	100	CETP
14	16	71403083	72845749	4	1	2.2e-08	8.1e-08	1.0e+00	100	TXNL4B
15	19	10283932	12191233	7	3	3.3e-13	7.0e-38	5.3e-12	71	C19orf80 EPOR LDLR
16	19	44614208	46098885	4	5	9.6e-13	5.0e-70	3.1e-44	38	APOC2 BCAM PVRL2 TOMM40
17	19	48464978	49872085	3	1	1.7e-08	1.1e-08	1.3e-01	93	NTN5
18	20	39720830	40229720	1	1	3.8e-08	1.2e-06	1.6e-01	92	LPIN3
19	20	61989111	62912463	3	1	8.2e-09	2.4e-08	6.7e-01	99	OPRL1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.39	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder or Schizophrenia	1.38	1	1	2.2	0.00	1.0e+00	FES
Intelligence (Savage-Jansen 2018)	0.83	1	0	0.0	0.00	1.0e+00	TXNL4B
Schizophrenia (2018)	1.22	1	1	2.2	0.00	1.0e+00	FES
Schizophrenia vs Biploar Disorder	0.96	1	0	0.0	0.00	1.0e+00	FNDC4
Alzheimer’s Disease (in mother)	9.09	4	4	8.9	1.00	3.6e-04	APOC2 BCAM PVRL2 TOMM40
Alzheimer’s Disease (in father)	3.49	3	1	2.2	0.00	1.0e+00	APOC2 PVRL2 TOMM40
Alzheimer’s Disease (including proxy)	14.31	4	4	8.9	0.99	9.8e-03	APOC2 BCAM PVRL2 TOMM40
Crohns Disease (2017)	2.22	3	2	4.4	0.00	1.0e+00	DOCK7 FNDC4 NTN5
Irritable Bowel Disease (IBD)	1.89	3	1	2.2	0.00	1.0e+00	FNDC4 NTN5 OPRL1
Ulcerative Colitis (UC)	1.54	1	1	2.2	0.00	1.0e+00	OPRL1
Breast Cancer	1.56	3	0	0.0	0.00	1.0e+00	ABO FES OPRL1
Ovarian Cancer	1.96	2	0	0.0	0.00	1.0e+00	ABO OPRL1
Body Mass Index (BMI) (2010)	1.93	1	0	0.0	0.00	1.0e+00	HMGCR
Coronary Artery Disease (CAD)	7.80	4	3	6.7	0.47	5.3e-01	EPOR LPL PSRC1 ZNF259
Crohns Disease (2012)	1.38	2	0	0.0	0.00	1.0e+00	DOCK7 FNDC4
Fasting Glucose	4.47	1	1	2.2	0.00	1.0e+00	FNDC4
HbA1C	1.62	1	0	0.0	0.00	1.0e+00	ABO
HDL Cholesterol	48.98	8	4	8.9	-0.63	9.5e-02	APOB APOC2 CETP LPL PSRC1 PVRL2 TOMM40 ZNF259
LDL Cholesterol	82.55	22	18	40.0	0.94	1.2e-11	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FNDC4 HMGCR LDLR LPIN3 LRPPRC NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Primary Biliary Cirrhosis	1.40	1	0	0.0	0.00	1.0e+00	EPOR
Rheumatoid Arthritis	1.62	1	0	0.0	0.00	1.0e+00	OPRL1
Schizophrenia (2014)	1.16	1	1	2.2	0.00	1.0e+00	FES
Triglycerides	54.56	11	8	17.8	0.72	1.2e-02	APOB APOC2 CETP DOCK7 FNDC4 LPL NAT2 PAFAH1B2 PVRL2 TXNL4B ZNF259
Ulcerative Colitis	1.46	1	0	0.0	0.00	1.0e+00	PAFAH1B2
Blood Eosinophil Count	1.78	11	5	11.1	-0.12	7.3e-01	ABO APOC2 BCAM DOCK7 EPOR LPL OPRL1 PAFAH1B2 PVRL2 TOMM40 ZNF259
Blood Platelet Count	4.01	13	9	20.0	-0.04	9.0e-01	ABO APOC2 DOCK7 FNDC4 HMGCR LPIN3 LPL NTN5 PAFAH1B2 PVRL2 TOMM40 TXNL4B ZNF259
Blood Red Count	5.52	7	4	8.9	-0.35	4.4e-01	ABCG5 ABO FES FNDC4 LPIN3 PVRL2 TXNL4B
Blood White Count	2.95	8	4	8.9	0.21	6.1e-01	ABO CETP DOCK7 FES FNDC4 LPIN3 PAFAH1B2 PVRL2
Heel T-Score	1.24	5	2	4.4	-0.87	5.5e-02	ABO DOCK7 HMGCR LPIN3 PSRC1
BMI	1.91	5	3	6.7	-0.40	5.1e-01	FNDC4 HMGCR LPL OPRL1 TXNL4B
Height	0.95	10	6	13.3	-0.74	1.5e-02	ABCG5 ABO APOC2 EPOR FES FNDC4 LPL NTN5 PSRC1 ZNF259
Waist Hip Ratio (WHR)	1.71	5	2	4.4	0.99	2.1e-03	LPIN3 LPL LRPPRC NTN5 OPRL1
Systolic Blood Pressure	4.12	7	3	6.7	0.76	4.7e-02	EPOR FES FNDC4 NTN5 OPRL1 PAFAH1B2 TOMM40
Smoking Status	1.33	1	0	0.0	0.00	1.0e+00	FES
Allergy or Eczema	1.75	5	0	0.0	0.77	7.3e-02	ABO APOC2 FES FNDC4 PVRL2
Cardiovascular Disease	12.52	19	17	37.8	0.95	1.1e-10	ABCG5 APOB BCAM DOCK7 EPOR FES FNDC4 HMGCR LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Hypothyroidism (self reported)	1.02	1	0	0.0	0.00	1.0e+00	NTN5
Respiratory disease	1.33	2	0	0.0	0.00	1.0e+00	ABO FES
Type 2 Diabetes (T2D) (2018)	3.21	2	1	2.2	0.00	1.0e+00	FNDC4 LPL
Lung FEV1/FVC ratio	1.08	2	2	4.4	0.00	1.0e+00	NTN5 PSRC1
Lung FVC	1.19	4	2	4.4	-0.47	5.3e-01	ABO FNDC4 OPRL1 PVRL2
Chronotype (morning person)	0.91	1	0	0.0	0.00	1.0e+00	NTN5
Hair Pigment	0.21	4	1	2.2	0.75	2.5e-01	EPOR FES FNDC4 OPRL1
Tanning	0.28	2	1	2.2	0.00	1.0e+00	EPOR FNDC4
Hand grip strength (left)	1.47	2	0	0.0	0.00	1.0e+00	FES PVRL2
Number of treatments/medications taken	4.58	6	0	0.0	0.95	4.3e-03	FES FNDC4 LDLR LRPPRC NTN5 PSRC1
Average weekly spirits intake	1.41	1	0	0.0	0.00	1.0e+00	NTN5
Sensitivity / hurt feelings	1.06	1	0	0.0	0.00	1.0e+00	FES
Relative age of first facial hair	1.57	1	1	2.2	0.00	1.0e+00	FNDC4
Systolic blood pressure, automated reading	2.93	2	2	4.4	0.00	1.0e+00	FES OPRL1
Angina	7.54	7	2	4.4	0.97	2.7e-04	ABCG5 APOC2 C19orf80 FES LPL OPRL1 PSRC1
Medication: Metformin	2.82	3	1	2.2	0.00	1.0e+00	ABO FNDC4 LPL
Diabetes (father)	2.24	1	0	0.0	0.00	1.0e+00	FNDC4
Diabetes (mother)	2.39	2	0	0.0	0.00	1.0e+00	FNDC4 PVRL2
Impedance of leg (right)	2.02	5	4	8.9	0.62	2.7e-01	ABO FES FNDC4 HMGCR OPRL1
Leg fat-free mass (left)	2.24	4	2	4.4	-0.89	1.1e-01	EPOR FES FNDC4 HMGCR
Trunk fat percentage	1.18	4	1	2.2	-0.60	4.0e-01	BCAM HMGCR PVRL2 TXNL4B
Hand grip strength (right)	1.48	3	0	0.0	0.00	1.0e+00	FNDC4 LRPPRC PVRL2
Age when periods started (menarche)	0.91	1	0	0.0	0.00	1.0e+00	NTN5
Heel bone mineral density (BMD) T-score, automated (left)	1.12	1	0	0.0	0.00	1.0e+00	ABO
High blood pressure	3.63	3	2	4.4	0.00	1.0e+00	FES NTN5 OPRL1
Hayfever, allergic rhinitis or eczema	1.86	3	0	0.0	1.00	5.1e-04	ABO FNDC4 PVRL2
Medication: Atenolol	3.57	1	1	2.2	0.00	1.0e+00	FES
Sitting height	1.24	5	1	2.2	-0.84	7.8e-02	ABCG5 ABO FNDC4 NTN5 TXNL4B
High blood pressure (mother)	2.99	1	1	2.2	0.00	1.0e+00	FES
Body mass index (BMI)	1.72	4	1	2.2	-0.60	4.0e-01	FNDC4 HMGCR PVRL2 TXNL4B
Impedance of leg (left)	2.20	6	4	8.9	0.30	5.6e-01	ABO FES FNDC4 HMGCR LPL OPRL1
Leg predicted mass (left)	2.25	4	2	4.4	-0.89	1.1e-01	EPOR FES FNDC4 HMGCR
Trunk fat mass	1.35	4	1	2.2	-0.57	4.3e-01	BCAM HMGCR PVRL2 TXNL4B
Waist circumference	1.68	4	1	2.2	-0.60	4.0e-01	FNDC4 HMGCR PVRL2 TXNL4B
Number of incorrect matches in round	1.47	2	0	0.0	0.00	1.0e+00	FES NAT2
Alcohol usually taken with meals	1.55	2	0	0.0	0.00	1.0e+00	FES LPIN3
Had menopause	1.63	1	0	0.0	0.00	1.0e+00	LPL
Had other major operations	1.53	1	0	0.0	0.00	1.0e+00	ABCG5
Forced vital capacity (FVC)	1.08	3	1	2.2	0.00	1.0e+00	ABO EPOR PVRL2
Heel bone mineral density (BMD) T-score, automated (right)	1.10	1	0	0.0	0.00	1.0e+00	ABO
Qualifications: None of the above	0.81	1	0	0.0	0.00	1.0e+00	DOCK7
Mouth/teeth dental problems	1.67	2	0	0.0	0.00	1.0e+00	DOCK7 NTN5
Heart attack	5.22	4	1	2.2	0.95	4.6e-02	C19orf80 FES LPL PSRC1
Allergy	1.94	3	1	2.2	0.00	1.0e+00	ABO FES PVRL2
Diabetes (self-reported)	2.48	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Ramipril	2.95	1	0	0.0	0.00	1.0e+00	FES
Illnesses of siblings	2.63	1	0	0.0	0.00	1.0e+00	FES
Weight	1.96	4	2	4.4	-0.67	3.3e-01	EPOR FNDC4 HMGCR TXNL4B
Impedance of arm (right)	1.98	4	2	4.4	0.93	6.5e-02	ABO FNDC4 HMGCR OPRL1
Arm fat percentage (right)	1.49	4	1	2.2	-0.33	6.7e-01	ABO HMGCR PVRL2 TXNL4B
Trunk fat-free mass	2.61	7	4	8.9	-0.63	1.3e-01	APOC2 CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Hip circumference	1.67	4	2	4.4	-0.62	3.8e-01	FNDC4 HMGCR OPRL1 TXNL4B
Alcohol intake versus 10 years previously	2.81	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Father's age at death	3.43	3	0	0.0	0.00	1.0e+00	FES LPL PSRC1
Hair/balding pattern: Pattern 3	0.84	1	0	0.0	0.00	1.0e+00	LPIN3
Forced expiratory volume in 1-second (FEV1)	1.27	3	1	2.2	0.00	1.0e+00	ABO EPOR PVRL2
Pulse rate	2.25	1	1	2.2	0.00	1.0e+00	FNDC4
Serious illness, injury or assault of a close relative in last 2 years	2.01	1	0	0.0	0.00	1.0e+00	NTN5
Mouth/teeth dental problems: Dentures	1.86	1	1	2.2	0.00	1.0e+00	NTN5
Asthma	1.10	1	0	0.0	0.00	1.0e+00	ABO
Medication: Cholesterol lowering	33.84	26	22	48.9	0.99	2.3e-22	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FES FNDC4 HMGCR IPO7 LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Illnesses of mother	3.58	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), Best measure	1.28	3	0	0.0	0.00	1.0e+00	ABO EPOR PVRL2
Impedance of arm (left)	2.08	4	2	4.4	0.94	6.1e-02	ABO FNDC4 HMGCR OPRL1
Arm fat mass (right)	1.73	4	1	2.2	-0.56	4.4e-01	FNDC4 HMGCR PVRL2 TXNL4B
Trunk predicted mass	2.62	7	4	8.9	-0.63	1.3e-01	APOC2 CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Standing height	0.98	6	2	4.4	-0.67	1.5e-01	ABCG5 APOC2 EPOR FNDC4 NTN5 PSRC1
Breastfed as a baby	1.41	1	0	0.0	0.00	1.0e+00	FES
Seen doctor (GP) for nerves, anxiety, tension or depression	1.53	1	1	2.2	0.00	1.0e+00	LPIN3
Hair/balding pattern: Pattern 4	1.00	1	0	0.0	0.00	1.0e+00	LPIN3
Birth weight of first child	2.36	2	1	2.2	0.00	1.0e+00	FES OPRL1
Peak expiratory flow (PEF)	1.42	2	2	4.4	0.00	1.0e+00	ABO NTN5
Blood clot in the leg (DVT)	3.90	1	1	2.2	0.00	1.0e+00	ABO
Headache pain in last month	1.60	1	0	0.0	0.00	1.0e+00	FES
Medication for cholesterol, blood pressure or diabetes	13.91	20	7	15.6	-0.96	8.4e-12	APOB BCAM C19orf80 CETP EPOR FES FNDC4 HMGCR IPO7 LDLR LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 TOMM40 TXNL4B ZNF259
Gout (self-reported)	4.76	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Amlodipine	1.88	1	1	2.2	0.00	1.0e+00	FES
Birth weight	1.75	2	1	2.2	0.00	1.0e+00	FES NTN5
Chronic bronchitis/emphysema (mother)	1.35	1	0	0.0	0.00	1.0e+00	BCAM
High blood pressure (siblings)	2.71	2	1	2.2	0.00	1.0e+00	FES FNDC4
Forced vital capacity (FVC), Best measure	1.16	3	0	0.0	0.00	1.0e+00	ABO EPOR PVRL2
Body fat percentage	1.26	4	1	2.2	-0.61	3.9e-01	BCAM HMGCR PVRL2 TXNL4B
Leg fat percentage (right)	1.23	3	1	2.2	0.00	1.0e+00	BCAM HMGCR TXNL4B
Arm fat-free mass (right)	2.57	6	2	4.4	-0.68	1.4e-01	CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Comparative body size at age 10	1.11	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Number of children fathered	1.78	1	0	0.0	0.00	1.0e+00	NTN5
Medication: Blood pressure	3.70	2	1	2.2	0.00	1.0e+00	FES OPRL1
Angina (self-reported)	7.63	7	3	6.7	0.97	2.0e-04	ABCG5 APOC2 C19orf80 FES LPL OPRL1 PSRC1
Medication: Allopurinol	4.05	1	1	2.2	0.00	1.0e+00	FNDC4
Heart disease (mother)	3.11	1	0	0.0	0.00	1.0e+00	FES
Whole body fat mass	1.48	4	1	2.2	-0.56	4.4e-01	BCAM HMGCR PVRL2 TXNL4B
Leg fat mass (right)	1.66	5	1	2.2	-0.60	2.9e-01	BCAM FNDC4 HMGCR PVRL2 TXNL4B
Arm predicted mass (right)	2.52	6	2	4.4	-0.67	1.5e-01	CETP EPOR FNDC4 HMGCR NTN5 PSRC1
Pulse rate, automated reading	2.96	3	1	2.2	0.00	1.0e+00	APOB BCAM FNDC4
Alcohol intake frequency.	4.22	3	2	4.4	0.00	1.0e+00	FNDC4 LPIN3 NTN5
Comparative height size at age 10	1.47	4	2	4.4	-0.77	2.3e-01	FNDC4 IPO7 NTN5 PSRC1
Medication: Aspirin	6.98	6	1	2.2	0.95	3.6e-03	C19orf80 EPOR FES LPL OPRL1 PSRC1
Hypertension (Self-reported)	3.72	3	3	6.7	0.00	1.0e+00	FES NTN5 OPRL1
Illnesses of father: Heart disease	7.02	6	2	4.4	0.90	1.4e-02	ABO EPOR FES LPL OPRL1 PSRC1
Whole body fat-free mass	2.47	4	3	6.7	-0.70	3.0e-01	EPOR FNDC4 HMGCR PSRC1
Leg fat-free mass (right)	2.23	5	2	4.4	-0.73	1.6e-01	EPOR FES FNDC4 HMGCR PSRC1
Arm fat percentage (left)	1.49	4	1	2.2	-0.35	6.5e-01	ABO HMGCR PVRL2 TXNL4B
Diabetes diagnosed by doctor	2.72	1	1	2.2	0.00	1.0e+00	FNDC4
Medication for cholesterol	7.62	11	2	4.4	-0.96	2.4e-06	DOCK7 FES FNDC4 HMGCR LDLR NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TXNL4B
Back pain experienced in last month	1.23	1	0	0.0	0.00	1.0e+00	APOB
Asthma (self-reported)	1.19	1	0	0.0	0.00	1.0e+00	ABO
Medication: Aspirin	7.17	6	2	4.4	0.95	3.9e-03	C19orf80 EPOR FES LPL OPRL1 PSRC1
Illnesses of father: None of the above (group 1)	3.73	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.62	2	0	0.0	0.00	1.0e+00	ABO PVRL2
Whole body water mass	2.50	4	2	4.4	-0.69	3.1e-01	EPOR FNDC4 HMGCR PSRC1
Leg predicted mass (right)	2.24	5	2	4.4	-0.73	1.6e-01	EPOR FES FNDC4 HMGCR PSRC1
Arm fat mass (left)	1.72	4	1	2.2	-0.56	4.4e-01	FNDC4 HMGCR PVRL2 TXNL4B
Number of self-reported non-cancer illnesses	4.93	4	1	2.2	1.00	4.8e-03	ABO FNDC4 NTN5 OPRL1
Guilty feelings	1.15	1	0	0.0	0.00	1.0e+00	LPIN3
Medication: Blood pressure	3.22	3	1	2.2	0.00	1.0e+00	FES NTN5 OPRL1
High cholesterol (Self-reported)	54.28	26	23	51.1	0.97	1.7e-17	ABCG5 ABO APOB APOC2 BCAM C19orf80 CETP DOCK7 EPOR FES FNDC4 HMGCR IPO7 LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Medication: Bendroflumethiazide	1.90	2	0	0.0	0.00	1.0e+00	FES NTN5
Medication: Atorvastatin	21.82	17	9	20.0	0.98	4.2e-12	ABO APOB BCAM C19orf80 DOCK7 EPOR FNDC4 HMGCR LPL LRPPRC NTN5 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Illnesses of father: High blood pressure	2.96	1	1	2.2	0.00	1.0e+00	FES
Basal metabolic rate	2.36	4	2	4.4	-0.72	2.8e-01	EPOR FNDC4 HMGCR PSRC1
Leg fat percentage (left)	1.22	3	1	2.2	0.00	1.0e+00	BCAM HMGCR TXNL4B
Arm fat-free mass (left)	2.47	5	2	4.4	-0.76	1.4e-01	EPOR FNDC4 HMGCR NTN5 PSRC1
Number of operations (self-reported)	1.40	1	0	0.0	0.00	1.0e+00	ABCG5
Risk taking	1.28	1	0	0.0	0.00	1.0e+00	LRPPRC
Diastolic blood pressure, automated reading	2.61	3	1	2.2	0.00	1.0e+00	ABO C19orf80 FES
Vascular/heart problems diagnosed by doctor	4.70	3	3	6.7	0.00	1.0e+00	FES NTN5 OPRL1
Cholesterol lowering medication	28.70	23	19	42.2	0.99	2.1e-20	ABCG5 ABO APOB APOC2 BCAM C19orf80 DOCK7 EPOR FNDC4 HMGCR LDLR LPIN3 LPL LRPPRC NAT2 NTN5 OPRL1 PAFAH1B2 PSRC1 PVRL2 TOMM40 TXNL4B ZNF259
Heart attack/myocardial infarction (self-reported)	5.24	4	1	2.2	0.95	4.7e-02	C19orf80 FES LPL PSRC1
Deep venous thrombosis (DVT) (self-reported)	3.82	1	1	2.2	0.00	1.0e+00	ABO
Heart disease (siblings)	3.48	3	0	0.0	0.00	1.0e+00	FES PSRC1 ZNF259
Impedance of whole body	2.10	3	3	6.7	0.00	1.0e+00	FNDC4 HMGCR OPRL1
Leg fat mass (left)	1.65	5	1	2.2	-0.61	2.7e-01	BCAM FNDC4 HMGCR PVRL2 TXNL4B
Arm predicted mass (left)	2.50	5	2	4.4	-0.77	1.2e-01	EPOR FNDC4 HMGCR NTN5 PSRC1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	1	0.029	1.4
GTEx	Adipose Visceral Omentum	1	0.049	1.5
GTEx	Adrenal Gland	0	0.000	1.5
GTEx	Artery Aorta	3	0.101	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Artery Tibial	3	0.080	1.5
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.4
GTEx	Brain Cerebellum	1	0.050	1.5
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Frontal Cortex BA9	0	0.000	1.5
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Hypothalamus	0	0.000	1.3
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	0	0.000	1.4
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.5
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.5
GTEx	Cells Transformed fibroblasts	5	0.119	1.5
GTEx	Colon Sigmoid	0	0.000	1.4
GTEx	Colon Transverse	0	0.000	1.4
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.4
GTEx	Esophagus Mucosa	7	0.211	1.5
GTEx	Esophagus Muscularis	3	0.093	1.5
GTEx	Heart Atrial Appendage	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Liver	2	0.279	1.7
GTEx	Lung	0	0.000	1.5
GTEx	Muscle Skeletal	2	0.069	1.5
GTEx	Nerve Tibial	2	0.046	1.4
GTEx	Ovary	0	0.000	1.5
GTEx	Pancreas	2	0.123	1.4
GTEx	Pituitary	0	0.000	1.4
GTEx	Prostate	0	0.000	1.5
GTEx	Skin Not Sun Exposed Suprapubic	2	0.081	1.5
GTEx	Skin Sun Exposed Lower leg	4	0.110	1.5
GTEx	Small Intestine Terminal Ileum	0	0.000	1.5
GTEx	Spleen	1	0.071	1.4
GTEx	Stomach	2	0.138	1.6
GTEx	Testis	0	0.000	1.5
GTEx	Thyroid	1	0.025	1.5
GTEx	Uterus	0	0.000	1.3
GTEx	Vagina	1	0.157	1.6
GTEx	Whole Blood	4	0.201	1.6
METSIM	Adipose	2	0.043	1.4
NTR	Blood	2	0.083	1.4
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.5
YFS	Blood	5	0.108	1.5
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.5
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	5	0.242	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	5	0.244	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	6	0.139	1.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.126	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.241	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.4
The Cancer Genome Atlas	Thyroid Carcinoma	5	0.097	1.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	1.7